Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820132 | 0.82 | ELANE (0.40) | PARP1GABRA1GABRB2LOXL2ALOX5AP | |
| SCHEMBL25820084 | 0.78 | ALOX5AP (0.37) | GABRA1GABRB2LOXL2ALOX5AP | |
| SCHEMBL25822467 | 0.75 | PARP1 (0.41) | PARP1GABRA1GABRB2ALOX5APCDK2 | |
| SCHEMBL25636291 | 0.75 | PARP1 (0.41) | PARP1GABRA1GABRB2HTR2CHTR2B | |
| SCHEMBL2494065 | 0.74 | LOXL2 (0.58) | LOXL2 | |
| SCHEMBL4619983 | 0.72 | PARP1 (0.44) | PARP1 | |
| SCHEMBL23479348 | 0.71 | PARP1 (0.41) | PARP1ALOX5APFEN1 | |
| SCHEMBL14010021 | 0.71 | LOXL2 (0.38) | GABRA1GABRB2LOXL2HTR2AHTR2C | |
| SCHEMBL12749711 | 0.69 | KDM4E (0.48) | GABRA1GABRB2LOXL2HSP90AB1HTR2A | |
| SCHEMBL21037109 | 0.69 | GABRA1 (0.47) | GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | PARP1 2894/4885GABRA1 3307/4885GABRB2 2323/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | PARP1 2205/4885GABRA1 3364/4885GABRB2 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.